WO2005072775A1 - 消炎鎮痛外用剤 - Google Patents
消炎鎮痛外用剤 Download PDFInfo
- Publication number
- WO2005072775A1 WO2005072775A1 PCT/JP2005/001540 JP2005001540W WO2005072775A1 WO 2005072775 A1 WO2005072775 A1 WO 2005072775A1 JP 2005001540 W JP2005001540 W JP 2005001540W WO 2005072775 A1 WO2005072775 A1 WO 2005072775A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- etodolac
- skin
- local anesthetic
- nsaid
- external preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention relates to an external preparation having an anti-inflammatory and analgesic effect.
- NSAID non-steroid anti-inflammatory drugs
- COX cyclooxygenase
- prostaglandins exert a variety of effects in addition to their effects such as inflammation and pain.If NSAID administration suppresses prostaglandin production more than necessary, severe side effects may occur. There is. For example, when the action of COX is suppressed, lipoxygenase activity is instead increased and leukotriene increases, resulting in a decrease in secretion of gastric juice and at the same time, an increase in active oxygen that destroys the gastrointestinal mucosa and ulceration. . Other side effects such as renal dysfunction, hepatic dysfunction, and skin rash are known, and aspirin asthma may be particularly life-threatening.
- NSAID has been developed as an external preparation that is less likely to cause these side effects.
- systemic side effects can be reduced and the drug concentration can be increased locally at the affected area.
- some NSAIDS have extremely poor skin permeability, and the effect when administered as an external preparation is extremely reduced compared to when administered orally. Therefore, various techniques for improving the skin permeability of NSAD have been studied.
- the invention described in Japanese Patent Application Laid-Open No. 14-128699 is an external anti-inflammatory and analgesic composition containing an NSAID and a local anesthetic, and has an object of improving skin permeability.
- a composition containing loxoprofen sodium, which is an NSAID, and a local anesthetic is prepared, and an evaluation test of the skin permeability is described.
- the preparation has high skin permeability
- the NSAID cannot penetrate and diffuse deep into the skin, the drug must remain at the surface of the skin, causing a decrease in safety due to skin irritation. May cause secondary disability.
- the concentration gradient with the drug existing outside the skin decreases, and the absorption efficiency decreases.
- the NSAID concentration in the conventional topical formulation has been at most about 1%. The effect was said to be saturated.
- WO01 / 047559 describes a topical patch containing a local anesthetic and an NSAID from the viewpoint of acting on both the inflammatory site and the peripheral nervous system.
- NSAIDs include indomethacin and the like. It is illustrated. However, there is no description about etodolac, and although the document discloses the results of functional tests as examples, there is no description about skin permeability and the like.
- WO 03/099293 also describes a salt formed from an NSAID having a carboxyl group and a local anesthetic having an amino group, and etodolac is described as an example of the NSAID.
- N the technology described in the literature is N It is intended to enhance the sustained release of drugs such as injections by reducing the water solubility of SAID, and is not intended for use as an external preparation. Therefore, there is no description or suggestion of skin permeability or permeability to muscle tissue.
- the only salt actually produced in the examples of the literature is one containing difunisal as an NSAID.
- COX mainly has type 1 and type 2 isozymes.
- COX-1 is constitutively expressed in most tissues in the body and is thought to play a role in maintaining the stability of the living body, such as in the protective action of the gastric mucosa.
- COX-2 normally has a low expression level, but is induced by inflammatory stimuli and the like. Therefore, it is thought that if COX-2 can be selectively inhibited, inflammation and the like can be reduced while suppressing biological damage.
- NSAID such as indomethacin diclofenac, which is specifically disclosed as an example in the above-mentioned prior art document, inhibits COX in a non-selective manner. Therefore, even if the skin permeability of these external preparations is increased, side effects associated with an increase in the blood concentration of the drug may become a problem, and the use of the external preparation becomes meaningless. Disclosure of the invention
- preparations containing NSAID and a local anesthetic have been known so far, and some external preparations containing loxoprofen have been designed to improve skin permeability.
- the behavior of a preparation containing an NSAID and a local anesthetic in muscle tissue is not uniform, and the coexistence of a local anesthetic reduces the penetration and diffusion of the NSAID. In some cases.
- the problem to be solved by the present invention is an external preparation containing NSAID, which not only has excellent skin permeability, but also has excellent permeability and diffusivity in tissues deeper than the skin, and has inflammation and pain.
- An object of the present invention is to provide an anti-inflammatory and analgesic external preparation that can act directly on a muscular or joint tissue having stiffness and has little skin irritation.
- the present inventors have conducted intensive studies on a preparation containing NSAID, particularly on a composition having excellent penetration and diffusion properties in muscle tissue and the like.
- a formulation that combines NSAID etodolac with a unique chemical structure and a local anesthetic The present inventors have found that the osmotic diffusivity in muscle tissue and the like is remarkably higher than other combined preparations, and completed the present invention.
- the anti-inflammatory analgesic external preparation of the present invention is characterized by containing etodolac and a local anesthetic.
- the ratio of the local anesthetic to 0.1 part by mass of etodolac is 0.1 to 1.5 parts by mass are preferable.
- Lidocaine is preferred as the local anesthetic. This is because the examples described later demonstrate that the combination with etodolac is suitable.
- the anti-inflammatory analgesic external preparation according to the present invention not only has excellent skin permeability, but also has remarkably improved permeability and diffusibility in deep skin such as muscle tissue.
- NSAID etodolac
- the effect can be exhibited as it is.
- skin irritation which has been a problem with conventional NSAID-containing external preparations, has also been reduced.
- the topical anti-inflammatory analgesic agent of the present invention includes chronic pain such as rheumatoid arthritis, osteoarthritis, and low back pain; inflammatory diseases such as shoulder periarthritis and tendonitis; neck and arm syndrome; It is extremely excellent as a preparation used for the treatment and treatment of.
- the anti-inflammatory analgesic external preparation of the present invention has a gist in that it contains etodolac and a local anesthetic.
- the etodolac used in the present invention has the chemical name 1, 8-getyl-1,3,4,9-tetrahydropyrano [3,4-B] indole-1-acetic acid. It has been used as an anti-inflammatory agent.
- a compound synthesized by a known method or a commercially available etodolac may be used.
- NSAIDs have many common chemical structures, indoleacetic acid such as indomethacin, salicylic acid such as difunisal, phenylpropionic acid such as loxoprofen, phenylacetic acid such as diclofenac, meloxicam, etc. Oxycamic acid type.
- etodolac known as a good NSAID, has a unique chemical structure as shown below and does not fall into any of these categories.
- Etodolac is also an excellent selective inhibitor of CO X-2. Therefore, although the external preparation of the present invention has excellent skin permeability, there is little concern about side effects even when the blood concentration increases when administered as an external preparation. In addition, since the external preparation of the present invention also has osmotic diffusivity in muscle tissue and the like, etodolac does not stagnate on the surface of the skin and is absorbed from the capillaries without increasing only the blood concentration. It can act locally.
- the “local anesthetic” used in the present invention is not particularly limited as long as it has been conventionally used as a local anesthetic for medical use.
- lidocaine is particularly preferred. This is because it has been demonstrated that excellent effects can be exhibited by the examples described later.
- the “local anesthetic” used preferably has a cationic group such as an amino group.
- the cation group and the carboxyl group of etodolac are ion-associated, thereby improving the pharmacokinetics by covering each ionic group with a hydrophobic part and improving skin permeability, penetration diffusion and skin irritation. This is because it is considered to be done.
- the amount of etodolac incorporated into the external preparation of the present invention is preferably 1 to 50% by mass based on the total external preparation. If the amount is less than 1% by mass, the analgesic effect may be insufficient, and if the amount is more than 50% by mass, side effects may tend to increase. Since the external preparation of the present invention has an improved permeation and diffusion property in muscle tissue and the like as well as the skin permeability of etodolac, the effect is not saturated, and the effect according to the amount can be exhibited. The amount is more preferably 3% by mass or more, particularly 5% or more. Preferred. For the same reason, the amount of the local anesthetic compounded in the external preparation of the present invention is preferably 1 to 50% by mass based on the total external preparation.
- the mixing ratio of etodolac and the local anesthetic in the external preparation of the present invention is not particularly limited, but the ratio of the local anesthetic to 1 part by mass of etodolac is preferably 0.1 to 1.5 parts by mass.
- the molar ratio of the two is not particularly limited, but it is preferable to mix them so that the molar ratio of the local anesthetic to etodolac 1 is 0.1 to 1.8. This is because in such a range, it is possible to improve the skin permeability and permeation diffusion of etodolac.
- the mixing ratio is more preferably about 0.2 part by weight or more and about 1.1 part by weight or less, and the molar ratio is more preferably about 0.2 or more and about 1.3 or less.
- the amounts of etodolac (molecular weight: 287.35) and lidocaine (molecular weight: 234.34) in the drug product are made equal, and the number of moles of lidocaine is slightly greater than the number of moles of etodolac. At most, the effects according to the present invention can be sufficiently exhibited.
- Examples of the dosage form of the external preparation according to the present invention include an ointment, a lotion, an aerosol, a plaster, an aqueous cataplasm and the like. There is no particular limitation.
- the external preparation of the present invention may optionally contain a base (eg, natural rubber, isoprene rubber, polyisobutylene, styrene-isoprene-styrene block copolymer, styrene-butadiene-styrene block copolymer, styrene-ethylene-butylene).
- a base eg, natural rubber, isoprene rubber, polyisobutylene, styrene-isoprene-styrene block copolymer, styrene-butadiene-styrene block copolymer, styrene-ethylene-butylene.
- rubbers such as styrene block copolymers, alkyl (meth) acrylate (co) polymers, poly (meth) acrylates, polyisobutylene, polybutene, and liquid polyisoprene; petrolatum, cetanol, beeswax, lanolin, fluid Oils such as paraffin, carboxyvinyl polymers, starch acrylate, sodium polyacrylate, carmellose sodium, water-soluble polymers such as polyethylene dalicol; crotamiton; getyl sebacate; , Excipients (eg , Sugars such as sucrose; starch derivatives such as dextrin; carmellose sodium ⁇ cellulose derivatives such as beam; water-soluble polymers such as xanthan gum, etc.), coloring agents, emulsifiers, thickeners, Wetting agents (for example, glycerin etc.), stabilizers (for example, parahydroxybenzoic acid esters such as methylparaben
- etodolac or a salt thereof with a local anesthetic or a salt thereof. Specifically, both are added to a solvent and mixed by stirring, or both are directly heated and mixed.
- the salt used here is not particularly limited as long as it is pharmacologically acceptable. Further, even when a salt is used as a raw material, it is considered that the object of the present invention is achieved by a strong interaction between etodolac and a local anesthetic.
- Salts of local anesthetics that can be used as the active ingredient of the present invention include, for example, hydrohalides such as hydrofluoride, hydrochloride, hydrobromide, and hydroiodide; nitrates; Inorganic acid salts such as chlorates, sulfates and phosphates; salts of lower alkanesulfonic acids such as methanesulfonate, trifluoromethanesulfonate and ethanesulfonate; benzenesulfonate, ⁇ -toluenesulfone Aryl sulfonates such as acid salts; amino acid salts such as ordinate and glutamate; and carboxylate salts such as fumaric acid, succinic acid, citric acid, tartaric acid, oxalic acid and maleic acid. Can be done.
- the hydrochloride can be most preferably used.
- the solvent is Those generally used in producing a product are preferred.
- an oil can be formed, and formulation can be performed without a solvent. For example, by mixing both in a mortar and grinding while mixing, an oily component can be formed with frictional heat.
- a local anesthetic may be used not only for the purpose of reducing skin irritation but also as a solubilizing agent or a solubilizing agent for etdorata. Furthermore, although the reason is not always clear, inclusion of these local anesthetics also improves the skin permeability and penetration and diffusion of etodolac.
- the above-mentioned mixture of etodolac and a local anesthetic may be mixed with a component synthesized according to each of the above-mentioned dosage forms.
- the production method may be a known method according to each dosage form.
- the anti-inflammatory analgesic external preparation of the present invention thus obtained can sufficiently exhibit its effects even when etodolac is added in a larger amount than the conventional external preparation containing etodolac.
- the drug does not accumulate on the surface of the skin and is less irritating to the skin.
- the drug is delivered to the affected area (muscle, joint tissue, etc.) be able to. Therefore, the external preparation of the present invention is an etodolac preparation which can be directly applied to an affected area such as chronic pain and has an excellent effect.
- the amount of the external preparation of the present invention varies depending on the type of the active ingredient contained, the condition and age of the patient, etc., but it is generally preferable to apply the composition to an adult once to several times a day. More preferably, it is applied once or twice a day, but the frequency of administration may be increased depending on the condition.
- the present invention will be described in more detail with reference to Examples. However, the present invention is not limited to the following Examples, and appropriate modifications may be made within a range that can conform to the purpose of the preceding and the following. All of them are included in the technical scope of the present invention.
- Table 1 According to the formulation ratio shown in Table 1, was dissolved etodolac etc. macrogol 4 0 0, the sample solution 1 containing Etodo Lata and re lidocaine were prepared test solution 2 containing etodolac alone.
- the numerical values in Table 1 are parts by mass. table 1
- the etodolac-containing test liquids 1 and 2 prepared in Production Example 1 were tested for permeation and diffusion properties to meat pieces.
- gauze was applied to a petri dish having a diameter of 9 cm, and 10 g of the test solution 1 or 2 was added.
- red beef was cut into a 2 ⁇ 2 ⁇ 4 cm rectangular parallelepiped, placed on a gauze such that 2 ⁇ 2 cm was the bottom surface, covered with a polyvinylidene chloride film, and allowed to stand at 4 ° C. for 48 hours.
- a tape formulation containing etodolaclidkine was prepared by a solvent method using toluene. That is, first, etodolac, lidocaine, and macrogol were heated and mixed at 40 ° C until they became clear. Separately, styrene-1-T-soprene-styrene block copolymer, liquid paraffin, alicyclic saturated hydrocarbon resin and dibutylhydroxytoluene are dissolved in toluene, and a mixture of etodolac and lidocaine is added and further mixed. Thus, a homogeneous melt was obtained.
- This melt was applied to a release film (polyester) so that the weight of the paste after drying was 100 g / m 2 using a coating machine, and then heated and dried to evaporate toluene.
- a support nonwoven fabric was attached to the obtained coated surface, and this was cut into a desired size to obtain a tape.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2554751A CA2554751C (en) | 2004-01-29 | 2005-01-27 | Anti-inflammatory analgesic for external use |
KR1020067012212A KR101074374B1 (ko) | 2004-01-29 | 2005-01-27 | 소염진통 외용제 |
US10/587,862 US7655687B2 (en) | 2004-01-29 | 2005-01-27 | Anti-inflammatory analgesic for external use |
AU2005209110A AU2005209110B2 (en) | 2004-01-29 | 2005-01-27 | Anti-inflammatory analgesic for external use |
AT05704361T ATE534405T1 (de) | 2004-01-29 | 2005-01-27 | Entzündungshemmendes analgetikum für die äussere anwendung |
CN2005800029846A CN1909929B (zh) | 2004-01-29 | 2005-01-27 | 消炎镇痛外用药 |
ES05704361T ES2372959T3 (es) | 2004-01-29 | 2005-01-27 | Analgésico anti-inflamatorio para uso externo. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004021232 | 2004-01-29 | ||
JP2004-021232 | 2004-01-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005072775A1 true WO2005072775A1 (ja) | 2005-08-11 |
Family
ID=34823785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/001540 WO2005072775A1 (ja) | 2004-01-29 | 2005-01-27 | 消炎鎮痛外用剤 |
Country Status (10)
Country | Link |
---|---|
US (1) | US7655687B2 (ja) |
EP (1) | EP1716868B1 (ja) |
KR (1) | KR101074374B1 (ja) |
CN (1) | CN1909929B (ja) |
AT (1) | ATE534405T1 (ja) |
AU (1) | AU2005209110B2 (ja) |
CA (1) | CA2554751C (ja) |
ES (1) | ES2372959T3 (ja) |
WO (1) | WO2005072775A1 (ja) |
ZA (1) | ZA200606824B (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005209110B2 (en) | 2004-01-29 | 2010-07-01 | Medrx Co., Ltd. | Anti-inflammatory analgesic for external use |
CN103271083B (zh) * | 2005-10-07 | 2017-08-11 | 阿拉巴马大学 | 多功能离子液体组合物 |
EP2128123A4 (en) * | 2007-01-29 | 2011-04-20 | Medrx Co Ltd | NON-STEROIDAL ANTI-INFLAMMATORY SALT AND ORGANIC AMINO COMPOUND AND USE THEREOF |
KR101547115B1 (ko) * | 2007-12-11 | 2015-08-25 | 가부시키가이샤 메드렉스 | 이온 액체화된 에토돌락의 테이프제 |
US20120135955A1 (en) * | 2009-07-24 | 2012-05-31 | The University Of Tokyo | External Preparation Containing NSAIDs And Method For Producing The External Preparation |
JP5856153B2 (ja) | 2011-05-10 | 2016-02-09 | 伊藤忠ケミカルフロンティア株式会社 | 非水性貼付剤 |
US9925264B2 (en) | 2011-05-10 | 2018-03-27 | Itochu Chemical Frontier Corporation | Non-aqueous patch |
US11786455B2 (en) | 2011-05-10 | 2023-10-17 | Itochu Chemical Frontier Corporation | Non-aqueous patch |
LT2823815T (lt) | 2011-09-27 | 2018-08-27 | Itochu Chemical Frontier Corporation | Nevandeninis pleistras |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH093071A (ja) * | 1995-06-13 | 1997-01-07 | American Home Prod Corp | S(+)−エトドラクの経口製剤 |
JP2002128699A (ja) * | 2000-10-26 | 2002-05-09 | Sankyo Co Ltd | 消炎鎮痛外用剤組成物 |
JP2003335663A (ja) * | 2002-05-20 | 2003-11-25 | Medorekkusu:Kk | 消炎鎮痛外用剤 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6440420U (ja) | 1987-09-04 | 1989-03-10 | ||
JP4774179B2 (ja) | 1999-12-27 | 2011-09-14 | 帝國製薬株式会社 | 外用貼付剤 |
US20030129208A1 (en) | 2002-01-07 | 2003-07-10 | Alberts David S. | Topical application of alpha-DFMO and anti-inflammatory drug for treatment of actinic keratoses |
AU2003227517A1 (en) * | 2002-05-23 | 2003-12-12 | Danmarks Farmaceutiske Universitet | Pharmacologically active salts |
US7166641B2 (en) * | 2002-10-02 | 2007-01-23 | Yung Shin Pharmaceutical Industrial Co., Ltd. | Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same |
JP2005082512A (ja) | 2003-09-05 | 2005-03-31 | Medorekkusu:Kk | イオン性の薬物の経皮吸収性を高めた外用剤 |
AU2005209110B2 (en) | 2004-01-29 | 2010-07-01 | Medrx Co., Ltd. | Anti-inflammatory analgesic for external use |
JP4807721B2 (ja) | 2004-01-29 | 2011-11-02 | 株式会社 メドレックス | 消炎鎮痛外用剤 |
-
2005
- 2005-01-27 AU AU2005209110A patent/AU2005209110B2/en not_active Ceased
- 2005-01-27 CA CA2554751A patent/CA2554751C/en not_active Expired - Fee Related
- 2005-01-27 EP EP05704361A patent/EP1716868B1/en not_active Not-in-force
- 2005-01-27 ES ES05704361T patent/ES2372959T3/es active Active
- 2005-01-27 AT AT05704361T patent/ATE534405T1/de active
- 2005-01-27 WO PCT/JP2005/001540 patent/WO2005072775A1/ja active Application Filing
- 2005-01-27 KR KR1020067012212A patent/KR101074374B1/ko not_active IP Right Cessation
- 2005-01-27 CN CN2005800029846A patent/CN1909929B/zh not_active Expired - Fee Related
- 2005-01-27 US US10/587,862 patent/US7655687B2/en not_active Expired - Fee Related
-
2006
- 2006-08-16 ZA ZA200606824A patent/ZA200606824B/xx unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH093071A (ja) * | 1995-06-13 | 1997-01-07 | American Home Prod Corp | S(+)−エトドラクの経口製剤 |
JP2002128699A (ja) * | 2000-10-26 | 2002-05-09 | Sankyo Co Ltd | 消炎鎮痛外用剤組成物 |
JP2003335663A (ja) * | 2002-05-20 | 2003-11-25 | Medorekkusu:Kk | 消炎鎮痛外用剤 |
Also Published As
Publication number | Publication date |
---|---|
CN1909929B (zh) | 2011-04-20 |
CA2554751C (en) | 2012-05-29 |
ES2372959T3 (es) | 2012-01-30 |
AU2005209110A1 (en) | 2005-08-11 |
CN1909929A (zh) | 2007-02-07 |
US7655687B2 (en) | 2010-02-02 |
KR101074374B1 (ko) | 2011-10-17 |
ATE534405T1 (de) | 2011-12-15 |
US20070054952A1 (en) | 2007-03-08 |
EP1716868A4 (en) | 2009-07-15 |
EP1716868B1 (en) | 2011-11-23 |
EP1716868A1 (en) | 2006-11-02 |
KR20060121213A (ko) | 2006-11-28 |
AU2005209110B2 (en) | 2010-07-01 |
CA2554751A1 (en) | 2005-08-11 |
ZA200606824B (en) | 2007-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1716868B1 (en) | Anti-inflammatory analgesic for external use | |
EP0974350B1 (en) | External preparation containing tranilast and process for producing the same | |
EP2872177B1 (en) | Diclofenac formulations | |
JP4807721B2 (ja) | 消炎鎮痛外用剤 | |
JP4620168B2 (ja) | イオン液体化したエトドラクのテープ剤 | |
US20070254887A1 (en) | Pharmaceutical Composition for Transdermal Administration of Perospirone | |
US11925621B2 (en) | Medicinal preparation for external use | |
KR100552649B1 (ko) | 펠비낙 함유 소염진통용 플라스터 | |
JP2005145932A (ja) | 消炎鎮痛外用剤 | |
JP2004323502A (ja) | 浸透拡散性に優れた消炎鎮痛外用剤 | |
KR20070059758A (ko) | 비스테로이드성 항염증제와 국소마취제를 포함하는 경피투여 조성물 | |
JP6459148B2 (ja) | 経皮吸収型製剤 | |
JP6512905B2 (ja) | フェンタニル含有貼付剤 | |
WO2017057541A1 (ja) | 経皮吸収型製剤 | |
JP2008231081A (ja) | ケトプロフェン含有外用剤 | |
WO2004012724A1 (ja) | 浸透拡散性に優れた消炎鎮痛外用剤 | |
JP2005213192A (ja) | 消炎鎮痛外用剤 | |
KR100216623B1 (ko) | 비스테로이드성 소염진통제의 외용약제 조성물 | |
KR20210133821A (ko) | 피록시캄을 함유하는 경피 흡수 제제 | |
CA2244679C (en) | Tranilast-containing preparation for external application and method of producing the same | |
BR122023027784A2 (pt) | Preparação medicinal para uso externo | |
JP2005213191A (ja) | 消炎鎮痛外用剤 | |
JPWO2003068239A1 (ja) | 新規外用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020067012212 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580002984.6 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2554751 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007054952 Country of ref document: US Ref document number: 10587862 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005704361 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005209110 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006/06824 Country of ref document: ZA Ref document number: 200606824 Country of ref document: ZA |
|
ENP | Entry into the national phase |
Ref document number: 2005209110 Country of ref document: AU Date of ref document: 20050127 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005209110 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005704361 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067012212 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 10587862 Country of ref document: US |